NCT01406444View on ClinicalTrials.gov

IGF-1 and Bone Loss in Women With Anorexia Nervosa

NACompletedINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

May 31, 2019

Study Completion Date

May 31, 2019

Conditions
Anorexia NervosaOsteopeniaOsteoporosis
Interventions
DRUG

rhIGF-1

Study participants will be started at a dose of 30 mcg/kg BID and will be titrated.

DRUG

Risedronate

Risedronate 35mg PO one time weekly

DRUG

Placebo

Placebo injections 30 mcg/kg BID, Placebo tablet PO once weekly

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT01406444 - IGF-1 and Bone Loss in Women With Anorexia Nervosa | Biotech Hunter | Biotech Hunter